“…Moreover, several reports have shown that FASN and related DNL enzymes play important roles in tumor cell survival at multiple levels (Chajes et al, 2006;Migita et al, 2009;Li et al, 2012a;Lin et al, 2013). In addition, over-expression of FASN or ACLY indicates poor prognosis of patients with malignancies, including breast cancer, nasopharyngeal carcinoma, colorectal, ovarian and prostate cancer, as well as NSCLC (Alo et al, 1996;Shurbaji et al, 1996;Ogino et al, 2008;Cerne et al, 2010;Rahman et al, 2012;Wang et al, 2012;Kao et al, 2013) .…”